A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.
BACKGROUND/AIM To assess preoperative blood levels of a biomarker panel in relation to the new classification system of epithelial ovarian cancer (EOC) type I and II. PATIENTS AND METHODS Preoperative plasma levels of B7 family protein homolog 4 (B7 H4) intact and cleaved soluble urokinase plasminogen activator receptor (suPAR) human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) were analyzed in 350 patients with adnexal lesions. RESULTS The levels of suPAR(II III) HE4, CA125 were all higher in EOC II than in EOC I, borderline and benign ovarian tumors. B7 H4 was increased in EOC II compared with benign ovarian tumors. The combination of suPAR(II III) HE4, CA125 and age in premenopausal women discriminates EOC and borderline tumors from benign tumors to higher accuracy compared to the Risk of Ovarian Malignancy Algorithm (p=0.007) CONCLUSION The biomarker panel suPAR(II III) HE4, CA125 and age in premenopausal women improved discrimination of malignant and benign ovarian tumors. The plasma levels of B7 H4 were increased in patients with EOC II compared to those with benign ovarian tumors.
Anticancer research